Compare YEXT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YEXT | MNPR |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.3M | 587.4M |
| IPO Year | 2017 | 2019 |
| Metric | YEXT | MNPR |
|---|---|---|
| Price | $6.47 | $85.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $7.50 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 1.0M | 102.0K |
| Earning Date | 06-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.82 | 54.99 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $170,201,000.00 | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | $2.46 | N/A |
| P/E Ratio | $43.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.27 | $50.07 |
| 52 Week High | $9.03 | $124.82 |
| Indicator | YEXT | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 25.28 |
| Support Level | $6.04 | $52.12 |
| Resistance Level | $7.99 | $123.37 |
| Average True Range (ATR) | 0.24 | 4.81 |
| MACD | -0.03 | -2.53 |
| Stochastic Oscillator | 71.13 | 3.00 |
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.